MedTrace Logo

VLDL-triglyceride Kinetics in Type 2 Diabetes

NCT01037647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2011-11-07

No results posted yet for this study

Summary

Type 2 diabetes is associated with diabetic dyslipidemia, which is a major risk factor for coronary heart disease. Triglycerides (TG) and cholesterol are transported in the system of lipoproteins, and the metabolism of these lipids in plasma is closely interrelated. Evidence suggests that increased concentration of very low-density lipoprotein triglyceride (VLDL-TG) is a central pathophysiological feature of the lipid and lipoprotein abnormalities in diabetic dyslipidemia.

The objective of this study was to investigate VLDL-TG kinetics and aspects of peripheral VLDL-TG metabolism, i.e. to what extent VLDL-TG associated fatty acids (FA) are oxidized or deposited in regional adipose tissue, in subjects with type 2 diabetes and healthy controls in the postabsorptive state and during acute hyperinsulinemia using ex-vivo labeled VLDL-TG tracers.

Conditions

Interventions

OTHER

Hyperinsulinemic euglycemic glucose clamp

Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).

Sponsors & Collaborators

  • The Danish Medical Research Council

    collaborator OTHER

  • The Novo Nordic Foundation

    collaborator OTHER

  • The Danish Diabetes Association

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Søren Nielsen, DMSc · Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037647 on ClinicalTrials.gov